OTSUKA
OTSKFNext catalyst
Bedaquiline (B)
Pulmonary Tuberculosis
Get an email about OTSKF's next catalysts
Track OTSUKA (OTSKF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 6 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
7 upcoming, 2 past
Bedaquiline (B) Phase 2 Est. Readout (PARADIGM4TB)
Estimated primary completion for Bedaquiline (B) trial (NCT06114628) in Pulmonary Tuberculosis. Topline data typically follows completion by weeks to months.
SourceSibeprenlimab Phase 2 Est. Readout (EnVISage)
Primary completion for Sibeprenlimab trial (NCT06928142) in Sjogren Disease
SourceIRL757 Phase 2 Est. Readout (LIFT-PD)
Estimated primary completion for IRL757 trial (NCT07461220) in PARKINSON DISEASE (Disorder). Topline data typically follows completion by weeks to months.
SourceCentanafadine XR Phase 3 Est. Readout
Estimated primary completion for Centanafadine XR trial (NCT07759154) in Attention-deficit/Hyperactivity Disorder. Topline data typically follows completion by weeks to months.
SourceEB-1020 (Centanafadine) low dose Phase 3 Est. Readout
Primary completion for EB-1020 (Centanafadine) low dose trial (NCT07087327) in Attention-Deficit Hyperactivity Disorder(ADHD)
SourceOPC-34712FUM/Brexpiprazole fumarate Phase 3 Est. Readout
Estimated primary completion for OPC-34712FUM/Brexpiprazole fumarate trial (NCT05325645) in Acute Schizophrenia. Topline data typically follows completion by weeks to months.
SourceJNT-517 Phase 3 Est. Readout
Primary completion for JNT-517 trial (NCT06628128) in Phenylketonuria (PKU)
SourceMarket Overview
Stock performance and key metrics
Tolvaptan (OPC-41061)
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
OPC-34712
Schizophrenia
Cilostazol
Vasospastic Angina
Centanafadine Hydrochloride
Attention-Deficit/Hyperactivity Disorder
AVP-786
Agitation in Patients With Dementia of the Alzheimer's Type
EB-1020 (Centanafadine)
Attention Deficit Hyperactivity Disorder (ADHD)
CDP870
Rheumatoid Arthritis
Centanafadine
Major Depressive Disorder
Tolvaptan Suspension
Autosomal Recessive Polycystic Kidney (ARPKD)
Hyalein Mini Ophthalmic solution
Dry Eye Syndromes
SEP363856
Schizophrenia
JNT-517
Phenylketonuria (PKU)
Antidepressant therapy
Major Depressive Disorder
OPC-41061(Tolvaptan)
Cardiac Edema
Ropinirole
Parkinson's Disease
Tolvaptan Oral Tablet
Syndrome of Inappropriate Antidiuretic Hormone Secretion
Aripiprazole orally
Schizophrenia
Meptin swinghaler
Asthma
Valproate
Bipolar Disorder Mania
Aripiprazole (Fixed dose)
Major Depressive Disorder
Quetiapine extended release
Schizophrenia
Aripiprazole
Schizophrenia
Tolvaptan Tablets
Autosomal Recessive Polycystic Kidney (ARPKD)
Busulfan
Multiple Myeloma
Aripiprazole (BMS-337039)
Dementia, Alzheimer Type
Aripiprazole+ ADT
Major Depressive Disorder
Olanzapine or Quetiapine or Risperidone
Schizophrenia
TEV-48125
Migraine
Antidepressant + Aripiprazole
Major Depressive Disorder
Procaterol, Salbultamol
Moderate Acute Asthma
Vadadustat
Anemia
OPC-12759 Ophthalmic suspension
Dry Eye Syndromes
Aripiprazole Low
Schizophrenia
Paroxetine CR
Depressive Disorder
Aripiprazole and aripiprazole once-monthly
Schizophrenia
OPC-6535
Crohn's Disease
OPC-34712FUM/Brexpiprazole fumarate
Acute Schizophrenia
Aripiprazole Oral Solution
Autistic Disorder
Aripiprazole (Abilify®) IM Depot Injection
Schizophrenia
OPC-34712 + ADT
Depressive Disorder
Aripiprazole IM Depot
Schizophrenia
Aripiprazole High
Schizophrenia
Asacol®
Ulcerative Colitis
AVP-786-18
Agitation in Participants With Dementia of the Alzheimer's Type
BPaQM
Pulmonary Tuberculosis
ETC-1002(bempedoic acid)
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Aripiprazole Mid
Schizophrenia
Aripiprazole (Titrated dose)
Major Depressive Disorder
Oral decitabine/cedazuridine
Myelodysplastic Syndromes
AVP-786-42.63
Agitation in Participants With Dementia of the Alzheimer's Type
Aripiprazole tablet
Schizophrenia
Centanafadine SR
Attention Deficit Disorder
Seroquel XR
Depressive Disorder
OPC-34712 Middle Dose
Acute Schizophrenia
OPC-34712 Low Dose
Acute Schizophrenia
Brexpiprazole, OPC-34712
Agitation Associated With
Mucosta Tab
Acute Gastritis
Subcutaneous azacitidine
Myelodysplastic Syndromes
Isoniazid (INH)
Tuberculosis, MDR
OPC-14597 (Aripiprazole)
Major Depressive Disorder
OPC-41061 (Tolvaptan)
Cardiac Edema
Aripiprazole depot
Schizophrenia
Escitalopram
Depressive Disorder
OPC-34712 High Dose
Acute Schizophrenia
Latanoprost ophthalmic solution
Glaucoma
OPC-6535 Tablets (drug)
Ulcerative Colitis
MCT-SR
Acute Gastritis
Abilify (Tablet)
Depression, Bipolar
High Dose Melphalan
Myeloma
Delamanid (DLM)
Tuberculosis, MDR
Rebamipide and Omeprazole
Gastric Ulcer
Meptin® Swinghaler
Asthma
OPC-1085EL ophthalmic solution
Glaucoma
Rebamipide
Keratoconjunctivitis Sicca
JNT-517 Tablet
Phenylketonuria (PKU)
Tolvaptan
Congestive Heart Failure
EB-1020 (Centanafadine) low dose
Attention-Deficit Hyperactivity Disorder(ADHD)
Nalmefene hydrochloride
Alcohol Dependence
Misoprostol
Rheumatoid Arthritis
OPC-1085EL
Open Angle Glaucoma or Ocular Hypertension
Venlafaxine XR
Depressive Disorder
Sibeprenlimab
IgA Nephropathy
OPC-12759
Dry Eye
Centanafadine XR
Attention-deficit/Hyperactivity Disorder
Ventolin® MDI
Asthma
Haloperidol
Bipolar Disorder
Brexpiprazole +ADT
Depressive Disorder
ADT
Major Depressive Disorder
EB-1020 (Centanafadine) high dose
Attention-Deficit Hyperactivity Disorder(ADHD)
Delamanid + OBR
Multidrug-resistant Tuberculosis
centanafadine capsule
Attention Deficit/Hyperactivity Disorder
Each subject will subcutaneously self-administer TEV 48125 at/monthly for a total of 2 doses
Migraine
Probucol
Hyperlipidemia
OPC-41061
Cirrhosis
SEP-363856
Schizophrenia
OPC-61815 injection
Congestive Heart Failure
ASC-01
Major Depressive Disorder
Certolizumab Pegol
Rheumatoid Arthritis
Lithium
Bipolar Disorder Mania
AVP-786-28
Neurobehavioral Disinhibition
OPA-15406
Atopic Dermatitis
OPC-61815
Congestive Heart Failure
Quabodepistat
Rifampicin-Resistant Pulmonary Tuberculosis
Brexpiprazole (OPC-34712)
Schizophrenia
Bedaquiline
Tuberculosis, Multidrug-Resistant
SPM 962
Idiopathic Restless Legs Syndrome
Pretomanid
Rifampicin-Resistant Pulmonary Tuberculosis
Brexpiprazole
Major Depressive Disorder
only Decitabine and cedazuridine
Myelodysplastic Syndromes
OPB-31121 phase2
Hepatocellular Carcinoma
Graft versus Host Disease prevention (GVHD prophylaxis)
Hematological Malignancies
Clofazimine
Tuberculosis, Multidrug-Resistant
High Dose-VIS649
Immunoglobulin A Nephropathy
OCV-501
Acute Myeloid Leukemia
Sodium hyaluronate ophthalmic solution
Keratoconjunctival Epithelial Disorder
Delamanid + Bedaquiline + OPC-167832
Pulmonary TB
OPB-31121
Hepatocellular Carcinoma
OPC-64005
Adult Attention Deficit Hyperactivity Disorder
OPC-249
Pain Due to Osteoporosis
IV busulfan
Multiple Myeloma
Optimized Background Regimen (OBR)
Tuberculosis, Pulmonary
13C-uracil
Dyspeptic Subjects
tetomilast (OPC-6535)
Chronic Obstructive Pulmonary Disease
Delamanid
Tuberculosis, Multidrug-Resistant
OPC-167832
Pulmonary TB
CTN SR
Attention Deficit Disorder With Hyperactivity
Cilostazol, Probucol
Peripheral Artery Disease
IV Decitabine
Myelodysplastic Syndromes
OPC-12759 ophthalmic
Dry Eye Syndromes
Calcium (13C)Carbonate
Gastric Acid-related Diseases
Gastric acid inhibitors
Gastroesophageal Reflux Disease
Tolvaptan MR
Autosomal Dominant Polycystic Kidney Disease
Tolvaptan IR
Autosomal Dominant Polycystic Kidney Disease
OPC-18
Hepatocellular Carcinoma
OPS-2071 tablet
Bacterial Enteritis
99mTc sulfur colloid
Dyspeptic Subjects
Delamanid Pediatric Formulation (DPF)
Multidrug Resistant Tuberculosis
OPC-67683
Pulmonary Tuberculosis
Rebamipide liquid
Head and Neck Cancer
OPS-2071
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Vesnarinone
Sarcoma, Kaposi
IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Lymphoma
OPC 131461 group
Cardiac Edema (CHF)
OPC-167832 + delamanid
Pulmonary TB
Low Dose-VIS649
Immunoglobulin A Nephropathy
OPC-167832 + BDQ
Pulmonary TB
Rifafour e-275
Pulmonary Tuberculosis
OPC-167832 + delamanid + BDQ
Pulmonary TB
Stimulant Therapy
Attention Deficit Hyperactivity Disorder
therapeutic allogeneic lymphocytes
Chronic Myeloproliferative Disorders
Rexulti
Borderline Personality Disorder
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
Depressive Disorder, Treatment-Resistant
Ponatinib OD
Chronic Myeloid Leukemia
OPDC-34712
Attention Deficit Hyperactivity Disorder
OPC-415
Multiple Myeloma (MM)
JNT-517 Suspension
Phenylketonuria
rabbit anti-thymocyte globulin (ATG)
Chronic Myeloproliferative Disorders
Aripiprazole + IEM (Ingestible Event Marker)
Schizophrenia
Busulfan, Fludarabine, Cytoxan
Lymphoma
busulfan, melphalan and fludarabine
Multiple Myeloma
PB
Autosomal Dominant Polycystic Kidney Disease
High-dose chemotherapy
Non-Hodgkin's Lymphoma
Flu/Bu4 conditioning regimen
Hematological Malignancies
OBR
Tuberculosis, Multidrug-Resistant
Linezolid (L)
Pulmonary Tuberculosis
Delpazolid (DZD)
Pulmonary Tuberculosis
Bedaquiline (B)
Pulmonary Tuberculosis
Aripiprazole tablet,, oral, 6 weeks
Schizophrenia
Risperidone tablet,, oral, 6 weeks
Schizophrenia
Moxifloxacin (M)
Pulmonary Tuberculosis
Delamanid (D)
Pulmonary Tuberculosis
Pretomanid (Pa)
Pulmonary Tuberculosis
Linezolid
Tuberculosis, Multidrug-Resistant
BTZ-043
Pulmonary Tuberculosis
Pyrazinamide (Z)
Pulmonary Tuberculosis
Quabodepistat (Q)
Pulmonary Tuberculosis
Optimized multidrug background regimen (OBR) for children with MDR-TB
Tuberculosis
Clofarabine/Busulfan x 4
Acute Myeloblastic Leukemia
IRL757
PARKINSON DISEASE (Disorder)
OPC-41601
Cirrhosis
Decitabine and cedazuridine
Myelodysplastic Syndromes
Medium Dose-VIS649
Immunoglobulin A Nephropathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tolvaptan (OPC-41061) | Phase 3 | Autosomal Recessive Polycystic Kidney Disease (ARPKD) | - | - |
OPC-34712 | Phase 3 | Schizophrenia | - | - |
Cilostazol | Phase 3 | Vasospastic Angina | - | - |
Centanafadine Hydrochloride | Phase 3 | Attention-Deficit/Hyperactivity Disorder | - | - |
AVP-786 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - | - |
EB-1020 (Centanafadine) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - | - |
CDP870 | Phase 3 | Rheumatoid Arthritis | - | - |
Centanafadine | Phase 3 | Major Depressive Disorder | - | - |
Tolvaptan Suspension | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) | - | - |
Hyalein Mini Ophthalmic solution | Phase 3 | Dry Eye Syndromes | - | - |
SEP363856 | Phase 3 | Schizophrenia | - | - |
JNT-517 | Phase 3 | Phenylketonuria (PKU) | - | - |
Antidepressant therapy | Phase 3 | Major Depressive Disorder | - | - |
OPC-41061(Tolvaptan) | Phase 3 | Cardiac Edema | - | - |
Ropinirole | Phase 3 | Parkinson's Disease | - | - |
Tolvaptan Oral Tablet | Phase 3 | Syndrome of Inappropriate Antidiuretic Hormone Secretion | - | - |
Aripiprazole orally | Phase 3 | Schizophrenia | - | - |
Meptin swinghaler | Phase 3 | Asthma | - | - |
Valproate | Phase 3 | Bipolar Disorder Mania | - | - |
Aripiprazole (Fixed dose) | Phase 3 | Major Depressive Disorder | - | - |
Quetiapine extended release | Phase 3 | Schizophrenia | - | - |
Aripiprazole | Phase 3 | Schizophrenia | - | - |
Tolvaptan Tablets | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) | - | - |
Busulfan | Phase 3 | Multiple Myeloma | - | - |
Aripiprazole (BMS-337039) | Phase 3 | Dementia, Alzheimer Type | - | - |
Aripiprazole+ ADT | Phase 3 | Major Depressive Disorder | - | - |
Olanzapine or Quetiapine or Risperidone | Phase 3 | Schizophrenia | - | - |
TEV-48125 | Phase 3 | Migraine | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
Procaterol, Salbultamol | Phase 3 | Moderate Acute Asthma | - | - |
Vadadustat | Phase 3 | Anemia | - | - |
OPC-12759 Ophthalmic suspension | Phase 3 | Dry Eye Syndromes | - | - |
Aripiprazole Low | Phase 3 | Schizophrenia | - | - |
Paroxetine CR | Phase 3 | Depressive Disorder | - | - |
Aripiprazole and aripiprazole once-monthly | Phase 3 | Schizophrenia | - | - |
OPC-6535 | Phase 3 | Crohn's Disease | - | - |
OPC-34712FUM/Brexpiprazole fumarate | Phase 3 | Acute Schizophrenia | - | - |
Aripiprazole Oral Solution | Phase 3 | Autistic Disorder | - | - |
Aripiprazole (Abilify®) IM Depot Injection | Phase 3 | Schizophrenia | - | - |
OPC-34712 + ADT | Phase 3 | Depressive Disorder | - | - |
Aripiprazole IM Depot | Phase 3 | Schizophrenia | - | - |
Aripiprazole High | Phase 3 | Schizophrenia | - | - |
Asacol® | Phase 3 | Ulcerative Colitis | - | - |
AVP-786-18 | Phase 3 | Agitation in Participants With Dementia of the Alzheimer's Type | - | - |
BPaQM | Phase 3 | Pulmonary Tuberculosis | - | - |
ETC-1002(bempedoic acid) | Phase 3 | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | - | - |
Aripiprazole Mid | Phase 3 | Schizophrenia | - | - |
Aripiprazole (Titrated dose) | Phase 3 | Major Depressive Disorder | - | - |
Oral decitabine/cedazuridine | Phase 3 | Myelodysplastic Syndromes | - | - |
AVP-786-42.63 | Phase 3 | Agitation in Participants With Dementia of the Alzheimer's Type | - | - |
Aripiprazole tablet | Phase 3 | Schizophrenia | - | - |
Centanafadine SR | Phase 3 | Attention Deficit Disorder | - | - |
Seroquel XR | Phase 3 | Depressive Disorder | - | - |
OPC-34712 Middle Dose | Phase 3 | Acute Schizophrenia | - | - |
OPC-34712 Low Dose | Phase 3 | Acute Schizophrenia | - | - |
Brexpiprazole, OPC-34712 | Phase 3 | Agitation Associated With | - | - |
Mucosta Tab | Phase 3 | Acute Gastritis | - | - |
Subcutaneous azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Isoniazid (INH) | Phase 3 | Tuberculosis, MDR | - | - |
OPC-14597 (Aripiprazole) | Phase 3 | Major Depressive Disorder | - | - |
OPC-41061 (Tolvaptan) | Phase 3 | Cardiac Edema | - | - |
Aripiprazole depot | Phase 3 | Schizophrenia | - | - |
Escitalopram | Phase 3 | Depressive Disorder | - | - |
OPC-34712 High Dose | Phase 3 | Acute Schizophrenia | - | - |
Latanoprost ophthalmic solution | Phase 3 | Glaucoma | - | - |
OPC-6535 Tablets (drug) | Phase 3 | Ulcerative Colitis | - | - |
MCT-SR | Phase 3 | Acute Gastritis | - | - |
Abilify (Tablet) | Phase 3 | Depression, Bipolar | - | - |
High Dose Melphalan | Phase 3 | Myeloma | - | - |
Delamanid (DLM) | Phase 3 | Tuberculosis, MDR | - | - |
Rebamipide and Omeprazole | Phase 3 | Gastric Ulcer | - | - |
Meptin® Swinghaler | Phase 3 | Asthma | - | - |
OPC-1085EL ophthalmic solution | Phase 3 | Glaucoma | - | - |
Rebamipide | Phase 3 | Keratoconjunctivitis Sicca | - | - |
JNT-517 Tablet | Phase 3 | Phenylketonuria (PKU) | - | - |
Tolvaptan | Phase 3 | Congestive Heart Failure | - | - |
EB-1020 (Centanafadine) low dose | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD) | - | - |
Nalmefene hydrochloride | Phase 3 | Alcohol Dependence | - | - |
Misoprostol | Phase 3 | Rheumatoid Arthritis | - | - |
OPC-1085EL | Phase 3 | Open Angle Glaucoma or Ocular Hypertension | - | - |
Venlafaxine XR | Phase 3 | Depressive Disorder | - | - |
Sibeprenlimab | Phase 3 | IgA Nephropathy | - | - |
OPC-12759 | Phase 3 | Dry Eye | - | - |
Centanafadine XR | Phase 3 | Attention-deficit/Hyperactivity Disorder | - | - |
Ventolin® MDI | Phase 3 | Asthma | - | - |
Haloperidol | Phase 3 | Bipolar Disorder | - | - |
Brexpiprazole +ADT | Phase 3 | Depressive Disorder | - | - |
ADT | Phase 3 | Major Depressive Disorder | - | - |
EB-1020 (Centanafadine) high dose | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD) | - | - |
Delamanid + OBR | Phase 3 | Multidrug-resistant Tuberculosis | - | - |
centanafadine capsule | Phase 3 | Attention Deficit/Hyperactivity Disorder | - | - |
Each subject will subcutaneously self-administer TEV 48125 at/monthly for a total of 2 doses | Phase 3 | Migraine | - | - |
Probucol | Phase 3 | Hyperlipidemia | - | - |
OPC-41061 | Phase 3 | Cirrhosis | - | - |
SEP-363856 | Phase 3 | Schizophrenia | - | - |
OPC-61815 injection | Phase 3 | Congestive Heart Failure | - | - |
ASC-01 | Phase 3 | Major Depressive Disorder | - | - |
Certolizumab Pegol | Phase 3 | Rheumatoid Arthritis | - | - |
Lithium | Phase 3 | Bipolar Disorder Mania | - | - |
AVP-786-28 | Phase 3 | Neurobehavioral Disinhibition | - | - |
OPA-15406 | Phase 3 | Atopic Dermatitis | - | - |
OPC-61815 | Phase 3 | Congestive Heart Failure | - | - |
Quabodepistat | Phase 3 | Rifampicin-Resistant Pulmonary Tuberculosis | - | - |
Brexpiprazole (OPC-34712) | Phase 3 | Schizophrenia | - | - |
Bedaquiline | Phase 3 | Tuberculosis, Multidrug-Resistant | - | - |
SPM 962 | Phase 3 | Idiopathic Restless Legs Syndrome | - | - |
Pretomanid | Phase 3 | Rifampicin-Resistant Pulmonary Tuberculosis | - | - |
Brexpiprazole | Phase 3 | Major Depressive Disorder | - | - |
only Decitabine and cedazuridine | Phase 2 | Myelodysplastic Syndromes | - | - |
OPB-31121 phase2 | Phase 2 | Hepatocellular Carcinoma | - | - |
Graft versus Host Disease prevention (GVHD prophylaxis) | Phase 2 | Hematological Malignancies | - | - |
Clofazimine | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
High Dose-VIS649 | Phase 2 | Immunoglobulin A Nephropathy | - | - |
OCV-501 | Phase 2 | Acute Myeloid Leukemia | - | - |
Sodium hyaluronate ophthalmic solution | Phase 2 | Keratoconjunctival Epithelial Disorder | - | - |
Delamanid + Bedaquiline + OPC-167832 | Phase 2 | Pulmonary TB | - | - |
OPB-31121 | Phase 2 | Hepatocellular Carcinoma | - | - |
OPC-64005 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder | - | - |
OPC-249 | Phase 2 | Pain Due to Osteoporosis | - | - |
IV busulfan | Phase 2 | Multiple Myeloma | - | - |
Optimized Background Regimen (OBR) | Phase 2 | Tuberculosis, Pulmonary | - | - |
13C-uracil | Phase 2 | Dyspeptic Subjects | - | - |
tetomilast (OPC-6535) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Delamanid | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
OPC-167832 | Phase 2 | Pulmonary TB | - | - |
CTN SR | Phase 2 | Attention Deficit Disorder With Hyperactivity | - | - |
Cilostazol, Probucol | Phase 2 | Peripheral Artery Disease | - | - |
IV Decitabine | Phase 2 | Myelodysplastic Syndromes | - | - |
OPC-12759 ophthalmic | Phase 2 | Dry Eye Syndromes | - | - |
Calcium (13C)Carbonate | Phase 2 | Gastric Acid-related Diseases | - | - |
Gastric acid inhibitors | Phase 2 | Gastroesophageal Reflux Disease | - | - |
Tolvaptan MR | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - | - |
Tolvaptan IR | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - | - |
OPC-18 | Phase 2 | Hepatocellular Carcinoma | - | - |
OPS-2071 tablet | Phase 2 | Bacterial Enteritis | - | - |
99mTc sulfur colloid | Phase 2 | Dyspeptic Subjects | - | - |
Delamanid Pediatric Formulation (DPF) | Phase 2 | Multidrug Resistant Tuberculosis | - | - |
OPC-67683 | Phase 2 | Pulmonary Tuberculosis | - | - |
Rebamipide liquid | Phase 2 | Head and Neck Cancer | - | - |
OPS-2071 | Phase 2 | Irritable Bowel Syndrome of Diarrhea Type (IBS-D) | - | - |
Vesnarinone | Phase 2 | Sarcoma, Kaposi | - | - |
IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) | Phase 2 | Lymphoma | - | - |
OPC 131461 group | Phase 2 | Cardiac Edema (CHF) | - | - |
OPC-167832 + delamanid | Phase 2 | Pulmonary TB | - | - |
Low Dose-VIS649 | Phase 2 | Immunoglobulin A Nephropathy | - | - |
OPC-167832 + BDQ | Phase 2 | Pulmonary TB | - | - |
Rifafour e-275 | Phase 2 | Pulmonary Tuberculosis | - | - |
OPC-167832 + delamanid + BDQ | Phase 2 | Pulmonary TB | - | - |
Stimulant Therapy | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
therapeutic allogeneic lymphocytes | Phase 2 | Chronic Myeloproliferative Disorders | - | - |
Rexulti | Phase 2 | Borderline Personality Disorder | - | - |
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) | Phase 2 | Depressive Disorder, Treatment-Resistant | - | - |
Ponatinib OD | Phase 2 | Chronic Myeloid Leukemia | - | - |
OPDC-34712 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
OPC-415 | Phase 2 | Multiple Myeloma (MM) | - | - |
JNT-517 Suspension | Phase 2 | Phenylketonuria | - | - |
rabbit anti-thymocyte globulin (ATG) | Phase 2 | Chronic Myeloproliferative Disorders | - | - |
Aripiprazole + IEM (Ingestible Event Marker) | Phase 2 | Schizophrenia | - | - |
Busulfan, Fludarabine, Cytoxan | Phase 2 | Lymphoma | - | - |
busulfan, melphalan and fludarabine | Phase 2 | Multiple Myeloma | - | - |
PB | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - | - |
High-dose chemotherapy | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Flu/Bu4 conditioning regimen | Phase 2 | Hematological Malignancies | - | - |
OBR | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
Linezolid (L) | Phase 2 | Pulmonary Tuberculosis | - | - |
Delpazolid (DZD) | Phase 2 | Pulmonary Tuberculosis | - | - |
Bedaquiline (B) | Phase 2 | Pulmonary Tuberculosis | - | - |
Aripiprazole tablet,, oral, 6 weeks | Phase 2 | Schizophrenia | - | - |
Risperidone tablet,, oral, 6 weeks | Phase 2 | Schizophrenia | - | - |
Moxifloxacin (M) | Phase 2 | Pulmonary Tuberculosis | - | - |
Delamanid (D) | Phase 2 | Pulmonary Tuberculosis | - | - |
Pretomanid (Pa) | Phase 2 | Pulmonary Tuberculosis | - | - |
Linezolid | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
BTZ-043 | Phase 2 | Pulmonary Tuberculosis | - | - |
Pyrazinamide (Z) | Phase 2 | Pulmonary Tuberculosis | - | - |
Quabodepistat (Q) | Phase 2 | Pulmonary Tuberculosis | - | - |
Optimized multidrug background regimen (OBR) for children with MDR-TB | Phase 2 | Tuberculosis | - | - |
Clofarabine/Busulfan x 4 | Phase 2 | Acute Myeloblastic Leukemia | - | - |
IRL757 | Phase 2 | PARKINSON DISEASE (Disorder) | - | - |
OPC-41601 | Phase 2 | Cirrhosis | - | - |
Decitabine and cedazuridine | Phase 2 | Myelodysplastic Syndromes | - | - |
Medium Dose-VIS649 | Phase 2 | Immunoglobulin A Nephropathy | - | - |
IV use
1 drug in this indication
Attention-deficit/Hyperactivity Disorder
1 drug in this indication
Immunoglobulin A Nephropathy
1 drug in this indication
Depressive Disorder
1 drug in this indication
Hepatocellular Carcinoma
1 drug in this indication
IgA nephropathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in OTSUKA's drug pipeline?→
CatalystAlert tracks 182 drug candidates in OTSUKA's (OTSKF) pipeline across Phase 3, Phase 2. Its lead program is Centanafadine XR (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OTSUKA's next FDA catalyst?→
OTSUKA's (OTSKF) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OTSKF biotech catalysts?→
Add OTSKF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OTSUKA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
